← Theriva Biologics, Inc. (TOVX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Theriva Biologics, Inc. (TOVX)
Pharmaceutical Preparations · market cap $11M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
4
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Theriva Biologics, Inc. (TOVX) is a micro-cap pharmaceutical company with a market capitalization of approximately $12M and a stock price near $0.24. The company maintains a pipeline spanning gastrointestinal and oncology indications, including SYN-004, SYN-010, and a nab-paclitaxel program for pancreatic adenocarcinoma, all at Phase 2 stage. No upcoming catalysts are on the calendar and no recent catalysts have been disclosed, leaving the investment case largely speculative.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-08-01 (est.)Phase 2 · VCN-01 oncolytic adenovirus (zabilugene almadenorepvec)imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) | Phase 2 | Pancreas Cancer, Metastatic |
| Period 1 - Treatment Sequence AB | Phase 2 | Healthy Volunteers |
| SYN-004 | Phase 2 | Healthy Volunteers With Ileostomy |
| SYN-010 | Phase 2 | Irritable Bowel Syndrome With Constipation (IBS-C) |
Price & technical context
3-month
-4.8%
6-month
-47.4%
12-month
-31.0%
52-wk range
$0.18–$0.41
vs 50-day MA
-13.0%
vs 200-day MA
-16.8%
Realized vol
106.2%
Max drawdown
-91.7%
Daily closes through 2026-10-23. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TOVX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.